Just saw BioMarin got FDA approval to expand PALYNZIQ for kids as young as 12 with PKU. Interesting move for the pediatric market—this enzyme therapy is basically the only option out there for managing blood phenylalanine levels, so expanding to younger patients makes sense from a treatment standpoint.

Stock jumped on the news initially, hit $61.73 (+1.01%), but then dropped pretty hard in after-hours trading down to $59.31. That's a wild swing. They're also pushing the European Medicines Agency for approval, which could open up more opportunities if they get the green light for adolescents in the EU.

The PKU formula space has been pretty quiet, so this expansion is kind of a big deal for families looking for alternatives. Curious if this changes the treatment landscape at all or if it's just a regulatory win for the company.